LT - N-acil-(3-pakeisto)-(8-pakeisto)-5,6-dihidro- [1,2,4]triazol[4,3-A]pirazinai, kaip selektyvūs NK-3 receptorių antagonistai, farmacinė kompozicija, būdai, skirti naudoti NK-3 receptoriaus sąlygotų sutrikimų gydymui
EN - N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
Legal status
Patent in force
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
C07D 487/04 |
(2006.01) |
|
|
A61K 31/4985 |
(2006.01) |
|
|
A61P 25/00 |
(2006.01) |
|
|
A61P 29/00 |
(2006.01) |
European patent
| (11) |
Number of the document |
2948455 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
14713844.0 |
|
Date of filing the European patent application |
2014-03-28 |
| (97) |
Date of publication of the European application |
2015-12-02 |
| (45) |
Date of publication and mention of the grant of the patent |
2017-09-27
|
| (46) |
Date of publication of the claims translation |
2017-11-27
|
PCT application
| (86) |
Number |
PCT/EP2014/056367 |
|
Date |
2014-03-28 |
PCT application publication
| (87) |
Number |
WO 2014/154895 |
|
Date |
2014-10-02 |
Priority applications
| (30) |
Number |
Date |
Country code |
|
13161863 |
2013-03-29
|
EP |
|
13193025 |
2013-11-15
|
EP |
|
14154303 |
2014-02-07
|
EP |
Inventors
| (72) |
HOVEYDA, Hamid, BE
DUTHEUIL, Guillaume, BE
FRASER, Graeme, BE
|
Grantee
| (73) |
Ogeda NV,
Medialaan 50, Vilvoorde 1800,
BE
|
Attorney or representative
| (74) |
Liucija JANICKAITĖ,
Inpatra UAB, Šeškinės g. 59-53, LT-07162 Vilnius,
LT
|
Title
| (54) |
N-acil-(3-pakeisto)-(8-pakeisto)-5,6-dihidro- [1,2,4]triazol[4,3-A]pirazinai, kaip selektyvūs NK-3 receptorių antagonistai, farmacinė kompozicija, būdai, skirti naudoti NK-3 receptoriaus sąlygotų sutrikimų gydymui |
| |
N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-03-04 |
12 |
289.00
EUR
|
Next renewal fee
|
2026-03-28 |
